Monthly Archives: June 2026

AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042

17/06/2026 – AB Science today announced that the United States Patent Office has formally granted a patent for methods of treating metastatic castrate resistant prostate cancer (mCRPC) with its lead compound masitinib

AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS

09/06/2026 – AB Science today announced that new analyses from its phase 3 trial in amyotrophic lateral sclerosis (AB10015) have been accepted for poster presentation at the ENCALS annual meeting (June 24-26, 2026, Madrid, Spain)

Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share

02/06/2026 – Stonegate Capital Partners updates its coverage of AB Science’s stock with a discounted cash flow valuation mid-point of EUR 4.25 per share